Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2

Trial Profile

Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacodynamics
  • Acronyms IMODALS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Primary endpoint (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in percentage of total lymphocytes) has been met.
    • 28 Apr 2017 Primary endpoint (Cell count (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in number) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top